A carregar...

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination

Medical therapy for clinical benign prostatic hyperplasia (BPH) has advanced significantly in the last 2 decades. Many new α1 antagonists and 5α reductase inhibitors (5ARi) are now commercially available. The practicing urologist must decide on the most appropriate medication for his patients, takin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Asian J Urol
Main Authors: Shum, Cheuk Fan, Lau, Weida, Teo, Chang Peng Colin
Formato: Artigo
Idioma:Inglês
Publicado em: Second Military Medical University 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5717968/
https://ncbi.nlm.nih.gov/pubmed/29264229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajur.2017.06.002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!